Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma

Renba Liang, MD\textsuperscript{1,2,3}, Liu Yang, MD\textsuperscript{1}, and Xiaodong Zhu, MD\textsuperscript{2,3,4}

Abstract

Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.

Keywords

epidermal growth factor receptor, nasopharyngeal carcinoma, nimotuzumab

Introduction

Nasopharyngeal carcinoma (NPC) is a malignant tumor with distinctive geographical distribution, which highly prevails in Southern China and South-East Asia.\textsuperscript{1} According to cancer statistics in 2018, about 129 000 new cases of NPC were diagnosed and more than 70% of that occurred in these areas.\textsuperscript{2} Radiotherapy and platinum-based chemotherapy are the backbone of NPC treatment.\textsuperscript{1} The therapeutic effect of patients has been greatly improved in the era of intensity-modulated radiotherapy (IMRT). Nevertheless, about 25% of cases develop into recurrence and metastasis after standard care.\textsuperscript{1,3} As a result, many studies have been performed to explore complementary therapy for NPC.

Epidermal growth factor receptor (EGFR), also named HER1 or ErbB1, is a member of ErbB family consisting of HER2/\textit{neu} (ErbB2), HER3 (ErbB3), and HER4 (ErbB4).\textsuperscript{4} EGFR is a 170 kDa transmembrane receptor and contains 3 domains, including extracellular, transmembrane, and intracellular domains. The extracellular region can recognize and bind to the corresponding ligand, and the intracellular part has tyrosine kinase activity.\textsuperscript{4} Once activated, EGFR forms homodimers or heterodimers with other ErbB family members, then phosphorylate tyrosine kinases and subsequently activate downstream signaling pathways such as RAS-RAF-ME-K-ERK, JAK-STAT and PI3K-AKT-mTOR. These signals ultimately result in tumor development and progression.\textsuperscript{5} (Figure 1) Therefore, EGFR seems to be a promising target in tumor treatment.

\textsuperscript{1} Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, People’s Republic of China
\textsuperscript{2} Department of Oncology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
\textsuperscript{3} Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People’s Republic of China
\textsuperscript{4} Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor, Guangxi Medical University, Ministry of Education, Nanning, Guangxi, People’s Republic of China

Corresponding Authors:
Liu Yang, Department of Oncology, Affiliated Hospital of Guangdong Medical University, No. 27 South of Ren Min Road, Zhanjiang 524200, Guangdong, People’s Republic of China.
Email: yangliugd@126.com
Xiaodong Zhu, Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71 He Di Road, Nanning 530021, Guangxi, China.
Email: zhuxiaodonggx123@126.com
It has been reported that EGFR is highly expressed in most NPC cases and is an independent factor of poor prognosis.\textsuperscript{6,7} As a consequence, several studies have evaluated the efficacy of EGFR-targeted therapies in NPC, including EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors. Nimotuzumab is a humanized EGFR monoclonal antibody invented in Cuba. Nimotuzumab recognizes and binds to extracellular domain of EGFR, and blocks the binding of other special ligands to EGFR and receptor autophosphorylation, ultimately leads to suppression of tumor growth.\textsuperscript{8} (Figure 2) Accumulating evidence has revealed that nimotuzumab exert promising antitumor activity as a single agent or combination with conventional therapy.\textsuperscript{9,10} In this review, we summarize the current clinical evidence of nimotuzumab in NPC treatment and deepen our understanding of management of the disease.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{signal_pathways.jpg}
\caption{The signaling pathways of EGFR. EGFR is activated through the binding of ligands. Activation of EGFR phosphorylates receptor-related tyrosine kinases in cytoplasm region, and then leads to the activation of downstream pathways, which are involved in cell proliferation, survival, invasion and metastasis.}
\end{figure}

\textbf{Nimotuzumab for Locoregionally Advanced NPC}

\textbf{COMBINATION With Concurrent Chemoradiotherapy (CCRT)}

Radiotherapy combined with chemotherapy is an important strategy for locoregionally advanced NPC. To probe the effects of combination of nimotuzumab and CCRT, a number of clinical trials have been performed (Table 1). In 2016, a retrospective study enrolling 42 patients (13 patients: 100mg/week; 29 patients: 200mg/week) demonstrated that 90.5\% of cases achieved complete response and 9.5\% of that had partial response. Regarding to side effects, there were 6 patients with grade 3/4 mucositis, 3 patients with grade 3/4 leukocytopenia and none had skin rash.\textsuperscript{11} These results suggested that adding...
Figure 2. The roles of nimotuzumab in tumor cells. Nimotuzumab can recognize and bind to extracellular domain of EGFR, which prevents the binding of ligands to receptor. Hence, EGFR signaling pathways is inhibited and this impairs tumor growth.

Table 1. The Studies of Combination Nimotuzumab and CCRT in Locoregionally Advanced NPC.

| References | Type                  | Treatment                                                                 | Cases | Outcomes                                      |
|------------|-----------------------|---------------------------------------------------------------------------|------|-----------------------------------------------|
| 11         | Retrospective         | Nimotuzumab plus cisplatin-based CCRT with and without IC, adjuvant chemotherapy | 42   | ORR (100%); 2-year LRFS (96.4%), DMFS (93.1%) and OS (96.6%).  
Grade 3/4 mucositis (14.3%); hematoloy toxicity (7.1%); no skin rash. |
| 12         | Prospective phase II  | IC and nimotuzumab plus CCRT                                             | 23   | 2-year PFS (83.5%) and OS (95.0%).  
Grade 3/4 mucositis (34.8%); grade 3 neutropenia (26.1%); no acne-like rash. |
| 13         | Retrospective         | IC and nimotuzumab plus CCRT                                             | 39   | 3-year LRF (92.1%), DMF (82.5%), PFF (77.6%) and OS (86.8%).  
Grade 3 mucositis (15.8%); no skin rash. |
| 15         | Prospective phase II  | Nimotuzumab plus CCRT                                                    | 49   | ORR (100.0%); 3-year OS (89.7%), DMFS (87.8%), LRC (97.9%) and PFS (85.7%).  
Grade 3 mucositis (8.2%); grades II xerostomia (20.4%).  
Nimotuzumab plus CCRT versus CCRT (5-year OS; 96.8% vs. 82.3%; P = 0.001), (5-year DMFS; 90.3% vs. 80.6%; P = 0.012), (5-year PFS; 83.9% vs. 71.0%; P = 0.006). |
| 14         | Retrospective         | 31 patients received nimotuzumab plus CCRT versus 62 patients received CCRT | 93   | No significant differences in toxicity.  
Nimotuzumab plus CCRT versus CCRT (5-year DMFS; 95.8% vs. 83.9%; P = 0.007), no significant differences in 5-year LRFS, PFS, OS.  
No significant differences in toxicity.  
Nimotuzumab plus CCRT versus CCRT (5-year DMFS; 93.09% versus 85.61%; P = 0.012), (5-year OS; 88.91% versus 78.30%; P = 0.006); no significant differences in 5-year LRFS, PFS.  
No significant differences in toxicity. |
| 17         | Retrospective         | Addition of IC to CCRT with or without nimotuzumab                       | 120 pairs | No significant differences in toxicity.  
Nimotuzumab versus no nimotuzumab (5-year DMFS; 95.8% vs. 83.9%; P = 0.007), no significant differences in 5-year LRFS, PFS, OS.  
No significant differences in toxicity.  
Nimotuzumab versus no nimotuzumab (5-year DMFS; 93.09% versus 85.61%; P = 0.012), (5-year OS; 88.91% versus 78.30%; P = 0.006); no significant differences in 5-year LRFS, PFS.  
No significant differences in toxicity. |
| 16         | Retrospective         | 184 patients received nimotuzumab and CCRT with or without IC, 546 patients received CCRT with or without IC | 730  | No significant differences in toxicity.  
Nimotuzumab versus no nimotuzumab (5-year DMFS; 93.09% versus 85.61%; P = 0.012), (5-year OS; 88.91% versus 78.30%; P = 0.006); no significant differences in 5-year LRFS, PFS.  
No significant differences in toxicity. |

Notes: Abbreviations: CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; ORR, objective response rate; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; OS, overall survival; PFS, progression-free survival; LRF, local recurrence-free; DMF, distant metastasis-free; PFF, progression failure-free; LRC, local-regional control.
Table 2. The evidence of addition nimotuzumab to IMRT in locoregionally advanced NPC.

| References | Type          | Treatment                                      | Cases | Outcomes |
|------------|---------------|------------------------------------------------|-------|----------|
| 22         | Retrospective | Nimotuzumab plus IMRT with or without chemotherapy | 75    | 3-year LRFS (95.6%), LRFS (95.5%), DMFS (98.6%), PFS (89.7%), and OS (89.2%). Grade 3/4 mucositis (12.0%); grade 3/4 leukocytopenia (34.7%); no skin rash. |
| 20         | Retrospective | IMRT plus nimotuzumab with or without concurrent chemotherapy | 50    | 2-year PFS (83.29%) and OS were (97.67%). Grade 3/4 mucositis (36.0%); nimotuzumab-related anaphylaxis (4.0%); no skin rash. |
| 21         | Retrospective | IC followed nimotuzumab plus IMRT               | 38    | 3-year LRFS (92.8%), DFS (89.5%), PFFS (78.7%), and OS (87.5%). Grade 3 mucositis (36.8%); no skin rash. |
| 19         | Retrospective | 231 patients received nimotuzumab plus IMRT with IC; 26 patients received nimotuzumab plus IMRT | 257   | 5-year LRFS (94.3%), RRFS (94.8%), DMFS (91.9%), PFS (83.4%), and OS (86.2%). Grade 3/4 mucositis (10.9%); grade 3/4 leukocytopenia (19.8%); no skin rash and infusion reaction. |
| 18         | Retrospective | After IC, 52 patients received nimotuzumab plus IMRT, 52 patients received cisplatin plus IMRT | 104   | (5-year OS; 63.9% vs. 81.4%; P = 0.024); (PFS; 58.0% vs. 80.6%; P = 0.028); no significant differences in OS and PFS for patients older than 60 years. Less leucopenia and milder nausea in nimotuzumab group. |

Note: IMRT, intensity-modulated radiotherapy; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; PFS, progression-free survival; OS, overall survival; PFFS, progression failure-free survival; IC, induction chemotherapy; RRFS, regional recurrence-free survival.

Addition Nimotuzumab to IMRT

To date, there are also some studies evaluating the efficacy and safety of addition nimotuzumab to IMRT in treatment.18-21 Wang et al19 demonstrated that 94.3% of 257 patients got 5-year local recurrence-free survival, 86.2% got 5-year overall survival and such regime did not give rise to accumulation of radiation-related toxicities after the treatment of combination nimotuzumab (100 mg or 200mg/week) and IMRT. Moreover, for the elderly patients (aged 60 or older), efficacy of this regime was also encouraging and it may be a better option for these patients who cannot be tolerate chemotherapy.22 Cisplatin is widely recommended for the use in concurrent chemoradiotherapy for patients with NPC.1 Therefore, it is crucial to compare efficacy and toxicity of nimotuzumab versus cisplatin concurrent with IMRT in patients. A retrospective study suggested that although cisplatin plus IMRT had better 5-year OS and progression-free survival (PFS) rates, the incidence of toxicity such as nausea and vomiting was higher when comparing to nimotuzumab (200mg/week) plus IMRT.18 However, in sub-analysis, there was no significant differences in OS and PFS for stage II patients and elderly patients.18

Combination With Induction Chemotherapy (IC)

IC followed by CCRT is recommend as level 2A evidence for locoregionally advanced NPC.23 Whether nimotuzumab plus IC benefit patients draws researchers’ attention. In a retrospective study, patients treating nimotuzumab (11% patients: 200mg/week; 89% patients: 200mg/week) plus IC followed by CCRT obtained high 5-year local recurrence-free survival rate (95.6%), distant metastases-free survival rate (91.7%), progression-free survival rate (84.0%), and overall survival rate (88.7%). Importantly, the side effects were tolerable, as evidenced by the fact that 6.2% (13/210) and 5.7% of patients suffered from grade3/4 mucositis and leukocytopenia, respectively.24 In addition, a multicenter randomized controlled study investigated the difference of safety and efficacy between nimotuzumab (200mg/week), cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil as induction therapy followed by CCRT. The nimotuzumab group had higher lymph node response rate (81% vs 60%) and lower toxicity compared with docetaxel group.25 Long-term efficacy, however, still requires further follow-up.

Given the encouraging therapeutic effects and tolerated toxicity of nimotuzumab in previous evidence, increasing phase II studies (NCT04223024, NCT03915132, NCT03557112) and
phase III study (NCT03837808) are being carried out to further verify the effectiveness of nimotuzumab in the management of locoregionally advanced NPC.

**Nimotuzumab for Recurrent or Metastatic NPC**

Nimotuzumab may also conferred benefit for patients with recurrent or metastatic NPC. In a multicenter, phase II clinical trial, patients overall objective response rate was 71.4% (25/35) and median PFS and OS were 7.0 (95% CI 5.8-8.2) months and 16.3 (95% CI 11.4-21.3) months, respectively after treatment with nimotuzumab (200mg/week), cisplatin plus 5-fluorouracil. The only grade 3/4 toxicity was leukopenia (62.9%). Surprisingly, a case experiencing NPC with multiple lung metastases obtained near-complete response and this situation lasted for 1 year after capcitabine plus nimotuzumab treatment. These data led us to draw a conclusion that regimes containing nimotuzumab may be an effective and feasible strategy for recurrent or metastatic NPC. This, however, warrants further prospective evaluation in the future.

**Conclusions**

To date, radiotherapy and platinum-based chemotherapy are the standard care for NPC. Although major improvement has been made in radiotherapy and chemotherapy modality, about 25% of patients still develop into treatment failure, including recurrence and metastasis. Hence, it is urge need to explore more therapeutic arrows to target NPC. Recently, nimotuzumab, a humanized monoclonal antibody targeting EGFR, has come into our fields of vision. A lot of clinical trials show encouraging advantages for patients with locoregionally advanced NPC as well as recurrent or metastatic NPC treated with nimotuzumab plus chemotherapy, radiotherapy, or concurrent chemoradiotherapy. What’s more, the toxicity in terms of grade 3/4 acne-like rash which is common in the use of other monoclonal antibody, is relatively few. However, most of studies discussed above are small sample size retrospective trials. It is noteworthy that many confounding factors existing in retrospective trials could interfere with the results of the researches. This highlights a need to design randomized, controlled, multicenter phase III clinical trials to further verify the clinical benefits and toxicity of nimotuzumab in the treatment of NPC.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Natural Science Foundation of China (81760544), the Key Research and Development Program Project of Guangxi Zhuang Autonomous Region (Grant No. GuikeAB18221007), and the Independent Project of Key Laboratory of Early Prevention & Treatment for Regional High-Incidence-Tumor (Grant No. GKE2019-17).

**ORCID iD**

Renba Liang, MD @ https://orcid.org/0000-0001-5050-8847

**References**

1. Chen YP, Chan A, Le QT, et al. Nasopharyngeal carcinoma. *Lancet*. 2019;394(10192):64-80. doi:10.1016/S0140-6736(19)30956-0
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424. doi:10.3322/caac.21492
3. Xiao WW, Huang SM, Han F, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. *Cancer*. 2011;117(9):1874-1883. doi:10.1002/cncr.25754
4. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. *Cancer Cell*. 2014;25(3):282-303. doi:10.1016/j.ccr.2014.02.025
5. Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. *Cancer Metastasis Rev*. 2017;36(3):463-473. doi:10.1007/s10555-017-9687-8
6. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. *Nat Rev Clin Oncol*. 2015;12(1):11-26. doi:10.1038/nrclinonc.2014.192
7. Meng DF, Xie P, Peng LX, et al. CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling. *J Exp Clin Cancer Res*. 2017;36(1):21. doi:10.1186/s13046-016-0483-z
8. Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. *Acta Pharmacol Sin*. 2007;28(9):1476-1493. doi:10.1111/j.1745-7254.2007.00681.x
9. Mazorra Z, Chao L, Lavastida A, et al. Nimotuzumab: beyond the EGFR signaling cascade inhibition. *Semin Oncol*. 2015;42(1):18-26. doi:10.1053/j.seminoncol.2018.04.008
10. Takeda M, Okamoto I, Nishimura Y, et al. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. *Semin Oncol*. 2018;45(1-2):18-26. doi:10.1053/j.seminoncol.2018.04.008
11. Liu ZG, Zhao Y, Tang J, et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. *Oncotarget*. 2016;7(17):24429-24435. doi:10.18632/oncotarget.8225
12. Huang JF, Zhang FZ, Zou QZ, et al. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial. *Oncotarget*. 2017;8(2):2457-2465. doi:10.18632/oncotarget.13899
13. Fangzheng W, Chuner J, Zhiming Y, et al. Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: experience of a single institution. *Oncol Res*. 2018;26(2):277-287. doi:10.3727/096504017X15079846743590

14. Yao JJ, Zhang LL, Gao TS, et al. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. *Cancer Biol Ther*. 2018;19(12):1102-1107. doi:10.1080/15384047.2018.1491501

15. Zhang S, Huang X, Zhou L, et al. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: a pilot study. *Medicine (Baltimore)*. 2018;97(38):e12503. doi:10.1097/MD.0000000000012503

16. Wang ZQ, Mei Q, Li JB, et al. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. *BMC Cancer*. 2019;19(1):1122. doi:10.1186/s12885-019-6156-5

17. Wang F, Sun Q, Jiang C, et al. Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis. *J Cancer*. 2018;9(3):594-603. doi:10.7150/jca.20461. eCollection 2018

18. Li HM, Li P, Qian YJ, et al. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. *BMC Cancer*. 2016;16(1):946. doi:10.1186/s12885-016-2974-x

19. Wang F, Jiang C, Ye Z, et al. Treatment outcomes of 257 patients with locoregionally advanced nasopharyngeal carcinoma treated with nimotuzumab plus intensity-modulated radiotherapy with or without chemotherapy: a single-institution experience. *Transl Oncol*. 2018;11(1):65-73. doi:10.1016/j.tranon.2017.11.002

20. Huang J, Zou Q, Qian D, et al. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma. *Onco Targets Ther*. 2017;10:5835-5841. doi:10.2147/OTT.S151554

21. Zhai RP, Ying HM, Kong FF, et al. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. *Onco Targets Ther*. 2015;8:3383-3390. doi:10.2147/OTT.S93238

22. Wang F, Jiang C, Ye Z, et al. Efficacy and safety of nimotuzumab plus radiotherapy with or without cisplatin-based chemotherapy in an elderly patient subgroup (aged 60 and older) with nasopharyngeal carcinoma. *Transl Oncol*. 2018;11(2):338-345. doi:10.1016/j.tranon.2018.01.013

23. Colevas AD, Yom SS, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. *J Natl Compr Canc Netw*. 2018;16(5):479-490. doi:10.6004/jnccn.2018.0026

24. Wang F, Jiang C, Ye Z, et al. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Oncotarget*. 2017;8(43):75544-75556. doi:10.18632/oncotarget.17357

25. Lu Y, Chen D, Liang J, et al. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study. *BMC Cancer*. 2019;19(1):1262. doi:10.1186/s12885-019-6459-6

26. Zhao C, Miao J, Shen G, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. *Ann Oncol*. 2019;30(4):637-643. doi:10.1093/annonc/mdz020

27. Yan S, Jiang X, Yang J, et al. Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. *Cancer Biother Radiopharm*. 2012;27(8):519-521. doi:10.1089/cbr.2012.1206

28. You R, Hua YJ, Liu YP, et al. Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. *Theranostics*. 2017;7(8):2314-2324. doi:10.7150/thno.19710